Recent results from the VOYAGE 1 trial, the first of 3 pivotal phase 3 studies, demonstrated psoriasis patients who were administered guselkumab (Janssen Research and Development, LLC) achieved higher proportions of cleared to minimal psoriasis compared with patients receiving the placebo or adalimumab (Humira ).
(Reuters) An experimental biotech drug developed by Johnson & Johnson proved more effective at clearing moderate to severe cases of the skin condition plaque psoriasis than a placebo or Abbvie Inc's big-selling Humira, according to data from a late stage study presented on Saturday.
The J&J drug, guselkumab, met the trial's primary goal, demonstrating statistically significant superior efficacy after 16 weeks of treatment and maintaining its advantage through week 48, the company said.
Modified rye bread with low FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides and polyols) can help to improve and control symptoms of irritable bowel syndrome (IBS), according to a new study from Finland.
Patients with psoriasis often have difficulty finding treatment plans that work despite numerous options and they experience a significant emotional toll due to the condition, according to a new national survey released by Health Union.1
The survey, Psoriasis in America 2016, was conducted between April 26, 2016, and June 18, 2016, and included 582 participants living with psoriasis (67% were diagnosed with plaque psoriasis, and 50% were diagnosed with psoriatic arthritis).
We each care for patients, teach, and conduct research in a specific, discipline-focused universe. When we come together to listen to, converse with, and understand the perspectives of experts from other medical disciplines within the autoimmune disease field, the boundaries of our knowledge are expanded, which in turn enriches our research, teaching, and care of patients.
There’s a growing realization that inflammatory diseases are not linked to any one organ system. So many specialties are involved, and each has insights. I first joined IAS because I am excited to learn from colleagues in other specialties. I keep coming back because of the new insights I gain each time I attend the IAS meeting.